Close Update: Stocks Extend Fed-Fueled Rally, End January With Sizable Gains

Shutterstock photo

Wall Street’s major averages were mixed at the close with the blue chip weighed down by earnings-related losses in DowDuPont ( DWDP ), while the S&P 500 and Nasdaq continued to gain mileage from the Federal Reserve’s dovish bias and upbeat corporate results from Facebook ( FB ).

After a dismal December, the benchmark indices all closed January with significant gains as the S&P 500 was up 7.9%, the Dow Jones Industrial Average higher by 7.2% and the Nasdaq taking the lead with a 9.7% increase from December.

Set in motion by the Fed’s adoption of a dovish ideology, stocks rallied with the help corporate earnings from Facebook and General Electric ( GE ) coupled with progress towards US/China trade.

Global bourses were mostly higher with China’s Shanghai underpinned by a slight improvement in the country’s manufacturing PMI, while downbeat retail sales left Germany’s DAX underwater. Italy’s FTSE MIB closed 0.21% lower after GDP data confirmed the Italian economy has fallen into a recession.

US markets were heavier at the open but sprang to life after the release of a better-than-expected 17% increase in new home sales and market-friendly US/China trade headlines.

Thursday’s other data included a surge in initial jobless claims due to the government shutdown; a 0.7% increase in the Q4 employment cost index; and two-year low in the Chicago PMI.


Dow Jones Industrial Average was down 15.19 points (-0.06%)

S&P 500 was up 23.46 points (+0.88%)

Nasdaq Composite Index was up 98.66 points (+1.37%)


FTSE 100 was up 0.39%

Nikkei 225 was up 1.06%

Hang Seng Index was up 1.08%

Shanghai China Composite Index was up 0.35%


(+) FBIO (+39.86%) Forms strategic partnership with Alexion ( ALXN ), Caelum Biosciences for CAEL-101

(+) AVP (+23.81%) Endorsed by portfolio manager Bill Miller

(+) GE (+11.65%) Q4 revenue tops estimate, misses on EPS

(+) FB (+10.82%) Tops Q4 estimates


(-) AVEO (-60.49%) Accepts FDA recommendation not to submit NDA for tivozanib with preliminary results from phase 3 Tivo-3 trial

(-) CODX (-39.29%) Selling 3.9 million shares to raise $5.5 million

(-) HRB (-7.56%) Downgraded at Goldman to sell from neutral, lowers PT to $22

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

Wealth Empire Newsletter
Register now for free updates and alerts

Subscribe By

Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.